miércoles, 23 de septiembre de 2020

EMA Panel Backs Baricitinib for Moderate-to-Severe Atopic Dermatitis

EMA Panel Backs Baricitinib for Moderate-to-Severe Atopic Dermatitis

Medscape Logo

EMA Panel Backs Baricitinib for Moderate-to-Severe Atopic Dermatitis

Megan Brooks
September 22, 2020

No hay comentarios:

Publicar un comentario